NAMS NewAmsterdam Pharma Company N.V

$22.80▲ +4.30% Healthcare Other
After hours $22.80▲ +0.00% Sep 11, 7:30 PM ET
Volume 1.60M Avg Volume (10D) 1.50M
Key Metrics & Fundamentals
Market Cap
$2.67B
P/E Ratio
–
Div Yield
–%
52W Range
21.23 - 42.21
% vs 50 MA
-20.79%
% vs 200 MA
-29.32%
RSI-14
31.8
MACD Histogram
-0.2900
Beta (1Y vs SPY)
1.13
Free Cash Flow
-$39.29M
Gross Rev
$3.70M
Gross Profit
$3.70M
EBITDA
-$59.72M
COGS
–
Operating Exp
$68.57M
Operating Income
-$64.86M
EBIT
-$64.86M
Pretax Income
-$64.14M
Net Income
-$64.14M
EPS (Diluted)
-0.55
Price & Volume History
Loading chart…
Recent News
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Investor's Business Daily · Sep 8, 2026 8:26 PM
Novartis Trial Failure Sparks Biopharma Options Frenzy
Schaeffer's Investment Research · Sep 8, 2026 4:07 PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 3, 2026 8:01 PM
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
GlobeNewswire · Sep 2, 2026 12:00 PM
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
GlobeNewswire · Aug 26, 2026 12:00 PM
RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating
MT Newswires · Aug 6, 2026 12:53 PM
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
MarketBeat · Aug 5, 2026 5:04 PM
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
Zacks · Aug 5, 2026 1:55 PM
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
GlobeNewswire · Aug 5, 2026 11:00 AM
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
GlobeNewswire · Jul 29, 2026 12:00 PM
Financial Overview - Income Statement Quarterly

See NAMS's money flow as a full page

Social Sentiment
Avg +0.40 · 2 posts
NewsDiscussion🧬 5 Biotech Catalysts I’m Watching This Month — May 18–30
r/StockMarket · May 17, 2025
Discussion of an underrated name with a high probability of success.
positive +0.60
NewsDiscussionFDA to phase out animal testing in drug development
r/wallstreetbets · Apr 10, 2025
The post’s discussion of NAMs data suggests a potential negative impact on companies relying on this methodology, however, this is only implied.
negative +0.20
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙